



Radiology: Volume 286: Number 2—February 2018 n radiology.rsna.org 643
1 From the Departments of Radiology (I.G.H.J., O.A.B., 
K.M.T., H.A.M., C.B.L.M.M., R.v.d.B.), Neurology 
(Y.B.W.E.M.R.), and Biomedical Engineering and Physics 
(H.A.M.), Academic Medical Center, PO Box 22660, 1100 
DD Amsterdam, the Netherlands; Department of Biomedical 
Sciences, Free University of Amsterdam, Amsterdam, the 
Netherlands (A.B.v.V.); Departments of Radiology (I.G.H.J., 
W.H.v.Z.) and Department of Neurology, Cardiovascular 
Research Institute Maastricht (CARIM) (R.J.v.O.), Maastricht 
University Medical Center, Maastricht, the Netherlands; 
Departments of Neurology (O.A.B., D.W.J.D.), Public Health 
(H.F.L.), and Radiology (A.v.d.L.), Erasmus MC University 
Medical Center, Rotterdam, the Netherlands; Department 
of Robotics and Mechatronics, University of Twente, En-
schede, the Netherlands (C.H.S.); Departments of Radiology 
(M.A.A.v.W.), and Neurology (I.R.v.d.W.), Leiden University 
Medical Center, Leiden, the Netherlands; and Department 
of Neurology, Medisch Centrum Haaglanden, Den Haag, the 
Netherlands (I.R.v.d.W.). Received November 10, 2016; re-
vision requested January 4, 2017; revision received April 6; 
accepted April 11; final version accepted June 2. Address 
correspondence to I.G.H.J. (e-mail: i.g.jansen@amc.nl).
2The complete list of MR CLEAN Investigators is given in 
Appendix E1 (online).
I.G.H.J. was supported by a personal grant from the Sticht-
ing Toegepast Wetenschappelijk Instituut voor Neuromodu-
latie (TWIN). The MR CLEAN trial was funded by the Dutch 
Heart Foundation and through unrestricted grants from 
AngioCare BV, Covidien/EV3, MEDAC Gmbh/LAMEPRO, and 
Penumbra.
q RSNA, 2017
Purpose: To assess the degree of cortical vein opacification in pa-
tients with internal carotid artery or middle cerebral 
artery (MCA) stroke and to evaluate the relationship with 
treatment benefit from intra-arterial therapy (IAT).
Materials and 
Methods:
Written informed consent was obtained from all patients 
in the Multicenter Randomized Clinical Trial of Endovas-
cular Treatment for Acute Ischemic Stroke in the Neth-
erlands. From the trial’s database, all patients (recruited 
from December 2010 until March 2014) with baseline 
computed tomographic (CT) angiograms were retrospec-
tively included. Enhancement of the vein of Labbé, sphe-
noparietal sinus, and superficial middle cerebral vein was 
graded by one neuroradiologist, as follows: 0, not visi-
ble; 1, moderate opacification; and 2, full opacification. 
The sum for the ipsilateral hemisphere was calculated, 
resulting in the cortical vein opacification score (COVES) 
(range, 0–6). Primary outcome was the modified Rankin 
Scale score at 90 days. Association with treatment accord-
ing to full cortical vein score and different dichotomized 
cutoff points was estimated with ordinal logistic regres-
sion. Interobserver agreement was assessed by two sepa-
rate observers who reviewed 100 studies each.
Results: In total, 397 patients were analyzed. Interaction of the 
cortical vein score with treatment was significant (P = 
.044) when dichotomized COVES was 0 versus more than 
0. The adjusted odds ratio for shift toward better func-
tional outcome was 1.0 (95% confidence interval [CI]: 
0.5, 2.0) for a COVES of 0 (n = 123) and 2.2 (95% CI: 
1.6, 4.1) for a COVES greater than 0 (n = 274). The mul-
tirater k value was 0.73.
Conclusion: In this study, patients with acute middle cerebral artery 
stroke with absence of cortical vein opacification in the 
affected hemisphere (COVES = 0) appeared to have no 
benefit from IAT, whereas patients with venous opacifica-
tion (COVES .0) were shown to benefit from IAT.
q RSNA, 2017
Clinical trial registration nos. NTR(1804) and 
ISRCTN10888758
Online supplemental material is available for this article.
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in which symmetry of the cortical veins 
implies tolerance of occlusion (18).
The purpose of this study was to as-
sess the degree of cortical vein opacifi-
cation in patients with internal carotid 
artery (ICA) or middle cerebral artery 
(MCA) stroke and to evaluate the rela-
tionship to treatment benefit from IAT. 
We hypothesized that diminished or 
absent cortical vein opacification is as-
sociated with reduced treatment benefit 
from IAT in patients with acute ischemic 
stroke in the proximal anterior circula-
tion and could therefore potentially be 
used to guide patient selection for IAT.
Materials and Methods
Study Design and Participants
We used the Multicenter Randomized 
Clinical Trial of Endovascular Treat-
ment for Acute Ischemic Stroke in the 
with abundant collateral flow have bet-
ter clinical outcomes and smaller infarct 
volumes after stroke (9–13). Because of 
this, collateral flow has been implement-
ed as a patient selection method in the 
Endovascular Treatment for Small Core 
and Anterior Circulation Proximal Occlu-
sion with Emphasis on Minimizing CT to 
Recanalization Times, or ESCAPE, trial, 
with the assumption that patients with 
poor collateral vessels would show min-
imal benefit from treatment (3).
The degree of opacification of ce-
rebral veins at computed tomographic 
(CT) angiography in patients with acute 
ischemic stroke has only sparsely been 
evaluated (14–16). In patients with 
acute ischemic stroke, opacification is 
usually asymmetric to some degree. It 
has been suggested that reduced venous 
opacification in the affected hemisphere 
represents delayed flow through the ce-
rebral microcirculation, which is indic-
ative of extensive local tissue damage 
(17). The degree of opacification could 
potentially be a better indicator for tol-
erance of occlusion than arterial collat-
eral vessel status, as the latter might 
not give an adequate reflection of the 
state of the cerebral microcirculation as 
it only assesses blood flowing into the 
tissue. The importance of venous drain-
age as an indicator of adequate collat-
eral and cerebral microcirculation has 
been acknowledged during balloon test 





CI = confidence interval
COVES = cortical vein opacification score
IAT = intra-arterial therapy
ICA = internal carotid artery
MCA = middle cerebral artery
MR CLEAN = Multicenter Randomized Clinical Trial of 
Endovascular Treatment for Acute Ischemic Stroke in the 
Netherlands
mRS = modified Rankin Scale
NIHSS = National Institutes of Health Stroke Scale
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Advances in Knowledge
 n The cortical vein opacification 
score (COVES) showed a signifi-
cant interaction with the effect of 
intra-arterial therapy (IAT) for 
patients with an acute proximal 
occlusion of the internal carotid 
artery (ICA) or middle cerebral 
artery (MCA) when dichoto-
mized between a COVES of 0 
(total absence of cortical vein 
opacification in the affected 
hemisphere) versus a COVES 
greater than 0 (P = .045).
 n In patients with a COVES of 0, 
there was no shift toward better 
functional outcome on the modi-
fied Rankin scale (adjusted 
common odds ratio [OR]: 1.0; 
95% confidence interval [CI]: 
0.5, 2.0), compared with a large 
shift for a COVES greater than 0 
(adjusted common OR: 2.2; 95% 
CI: 1.6, 4.1).
 n The mortality rates in patients 
with a COVES of 0 at 7 days and 
30 days after IAT (18.7% and 
26.0%, respectively) were higher 
than those in patients with a 
COVES greater than 0 (5.8% and 
13.4%, respectively) (P  .001 at 
7 days and P = .004 at 30 days).
 n Interobserver agreement for the 
entire COVES was substantial, 
with a quadratic weighted multi-
rater k value of 0.73 (95% CI: 
0.68, 0.79).
Implications for Patient Care
 n Assessment of cortical vein 
opacification could provide infor-
mation about the amount of sal-
vageable brain tissue during an 
acute proximal occlusion of the 
ICA or MCA.
 n Cortical vein opacification assess-
ment could be applied to patient 
selection for IAT in patients with 
an acute proximal occlusion of 
the ICA or MCA.
 n Selecting patients for IAT accord-
ing to degree of cortical vein 
opacification could potentially 
lead to better functional outcome 
and more brain tissue saved.
The benefit of intra-arterial therapy (IAT) for patients with a proven proximal intracranial arterial occlu-
sion treated within a 6-hour time window 
has recently been shown in several large 
randomized controlled trials (1–5). How-
ever, a substantial number of patients 
treated with IAT did not reach functional 
independence after 90 days, despite rel-
atively high recanalization rates in these 
studies. This underlines the need for 
simple and more reliable selection of pa-
tients who will benefit from IAT.
Cerebral collateral flow has been 
shown to be associated with IAT effect 
(6–8). Many studies suggest that patients 
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no dichotomization was performed for 
higher cutoff values. We tested model 
fit for all cutoff values and for the linear 
and categorical full COVES on the basis 
of the Akaike Information Criterion and 
the log likelihood (Table E2 [online]). 
We selected the model with the best fit 
for further analysis.
Interobserver Analysis
A random subset of 100 scans was 
graded by two additional observers 
(neuroradiologist W.v.Z., with .10 
years of experience, and neurologist 
I.v.d.W., with ,5 years of experi-
ence). Agreement beyond chance was 
estimated by using quadratic weighted 
multirater Fleiss k statistics on the full 
range COVES, with correction for the 
k paradox (19). Disagreement entailed 
a difference of one category between 
observers. Agreement for dichotomous 
cutoff values was estimated by using un-
weighted k statistics.
Statistical Analysis
Differences in baseline parameters 
were assessed by using the x2 test for 
categorical variables or the Student t 
test or Mann-Whitney U test for con-
tinuous variables. The primary effect 
parameter was the adjusted common 
odds ratio (OR) for a shift in the direc-
tion of a better outcome on the mRS, 
which was estimated with multivariable 
ordinal logistic regression analysis. The 
adjusted common OR and all second-
ary effect parameters were adjusted for 
major prespecified prognostic variables 
adapted from the original trial protocol 
statistical analysis plan: age, NIHSS at 
baseline, time of onset to randomiza-
tion, presence of previous stroke, atrial 
fibrillation, diabetes mellitus, and ICA 
terminus occlusion. The unadjusted 
and adjusted common ORs were re-
ported with 95% confidence intervals 
(CIs) to indicate statistical precision. 
Binary outcomes were analyzed with 
logistic regression and reported as un-
adjusted and adjusted common ORs 
with 95% CIs. P < .05 was considered 
indicative of a statistically significant 
difference. All P values were calculated 
for two-sided tests. Statistical analyses 
were performed with software (SPSS, 
were analyzed, enabling evaluation of 
the representative venous outflow net-
work of the MCA territory. These were 
the superficial middle cerebral vein, the 
vein of Labbé, and the sphenoparietal 
sinus. These veins were chosen because 
they account for nearly all venous drain-
age from the MCA territory and show 
a limited anatomic variability compared 
with other cortical veins. In case of ab-
sence of opacification of a cortical vein 
on the contralateral side owing to an 
anatomic variation, this was reflected in 
a lower maximum venous score. On the 
affected side, however, anatomic vari-
ations could not be determined with 
certainty, especially in case of complete 
absence of cortical vein opacification. 
Cortical vein opacification was graded 
per vein with baseline CT angiography 
by using a three-point scale, as follows: 
0, complete absence of cortical vein 
opacification; 1, moderate opacifica-
tion (defined as approximately half the 
attenuation of one of the target veins 
on the contralateral side); and 2, full 
opacification. For the affected hemi-
sphere, the sum of the grades for all 
three veins resulted in the cortical vein 
opacification score (COVES) and could 
add up to a maximum of six (all veins 
fully opacified). The total absence of 
venous opacification in a hemisphere 
was reflected by a score of 0. Exam-
ples of COVES assessment are shown 
in Figures 1 and 2. Isolated opacifica-
tion of only the most medial part of the 
sphenoparietal sinus in close proximity 
to the cavernous sinus (without opaci-
fication of the more lateral part of the 
sphenoparietal sinus or the superficial 
middle cerebral vein) was not consid-
ered as venous filling. All baseline CT 
angiograms were graded by one neuro-
radiologist (R.v.d.B.). The reader was 
blinded to clinical findings.
Association with Treatment Effect
We tested for interaction between 
COVES and treatment effect, using 
the full range of 0–6, and by using 
different dichotomous cutoff values 
(grade 0 vs grade .0; grade 0–1 vs 
grade .1; grade 0–2 vs grade .2; and 
grade 0–3 vs grade .3). Because of 
the possibility of anatomic variations, 
Netherlands (MR CLEAN) dataset for 
this post hoc analysis. Patient eligibility 
and methods used for MR CLEAN have 
been described previously (1), including 
the provision of informed consent and the 
approval of the study by a central medical 
ethics committee and the research board 
of each participating center.
In MR CLEAN, which ran between 
December 2010 and March 2014, pa-
tients with a proximal arterial occlu-
sion in the anterior circulation demon-
strated at vessel imaging who could be 
treated within 6 hours after symptom 
onset were randomized to receive IAT 
(intervention group) or usual care (no 
IAT) (control group). The median pa-
tient age was 66 years (interquartile 
range, 55–76 years); 58.4% of the 500 
patients were men.
Specific inclusion criteria for the 
present substudy were the presence of 
ICA, ICA terminus, or MCA (segment 
M1 or M2) occlusion as confirmed at CT 
angiography. All included patients were 
assessed by a neuroradiologist (R.v.d.B., 
with .10 years of experience) to deter-
mine if the timing of CT angiography 
was adequate for evaluating the venous 
system, as reflected by evident contrast 
material opacification of one of the sig-
moid sinus jugular bulbs, as well as to 
determine the location of the occlusion. 
Patients without adequate timing with 
solely an occlusion of the anterior cere-
bral artery were excluded from analysis.
Outcomes
The primary outcome parameter was 
the modified Rankin scale (mRS) score, 
a seven-point scale ranging from 0 (no 
symptoms) to 6 (dead), at 90 days. An 
mRS score of 2 or less is indicative of 
functional independence of the patient.
Secondary outcomes were stroke 
severity after 24 hours (National Insti-
tutes of Health Stroke Scale [NIHSS]), 
recanalization at vessel imaging after 24 
hours, and final infarct volume at unen-
hanced follow-up CT after 3–5 days (or 
1 day if this was not available due to 
death or discharge).
Imaging Assessment
All CT angiography protocols are pro-
vided in Table E1 (online). Three veins 
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version 22.0 for Windows; IBM, Ar-
monk, NY).
Results
Patients were recruited from Decem-
ber 2010 until March 2014. For this 
post hoc analysis, 397 patients met the 
study specific inclusion criteria—216 
(54%) in the intervention group and 
181 (46%) in the control group. In 101 
excluded patients, timing of CT angiog-
raphy hindered good assessment of the 
cortical venous system. Two patients 
were excluded because they only had 
anterior cerebral artery occlusion.
Association with Treatment Effect
The results of the interaction analysis 
for the COVES and the different di-
chotomized cutoff values are shown in 
Table 1. The distribution of patients on 
the full range of the COVES was as fol-
lows: COVES 0, 123 patients; COVES 
1, 80 patients; COVES 2, 90 patients; 
COVES 3, 42 patients; COVES 4, 32 pa-
tients; COVES 5, 17 patients; and COVES 
6, 13 patients. For a COVES of 0 (n = 
123) versus a COVES greater than 0 
(n = 271), the association with IAT 
Figure 2
Figure 2: Image from baseline CT angiography 
in 61-year-old man with left-sided occlusion. In 
affected hemisphere, sphenoparietal sinus is moder-
ately opacified, resulting in opacification grade of 1 
(white arrow). In unaffected hemisphere, sphenopar-
iatal sinus is fully opacified, with opacification grade 
of 2 (black arrow).
Table 1
Results of Interaction Analysis with Different Cutoff Values
COVES Cutoff Value Unadjusted Analysis Adjusted Analysis*
Full COVES .070 .179
0 (n = 123) vs . 0 (n = 274) .005 .044
0–1 (n = 203) vs .1 (n = 194) .190 .276
0–2 (n = 293) vs .2 (n = 104) .192 .262
0–3 (n = 335) vs .3 (n = 62) .784 .941
Note.—Data are P values. One hundred twenty-three patients had COVES of 0, 80 had COVES of 1, 90 had COVES of 2, 42 had 
COVES of 3, 32 had COVES of 4, 17 had COVES of 5, and 13 had COVES of 6.
* Adjusted for prespecified prognostic variables.
Figure 1
Figure 1: Images from baseline CT angiography in 61-year-old man with right-sided segment M1 occlusion. 
(a) Image shows abundant arterial collateral flow in affected hemisphere (grade 3). Patient had moderate dis-
ability 90 days after IAT (mRS score, 4). (b–d) Images in unaffected hemisphere show full opacification (arrow) 
of sphenoparietal sinus (b), superficial middle cerebral vein (c), and vein of Labbé (d). However, opacification 
was absent in all three cortical veins in affected hemisphere. This resulted in a COVES of 0 for this patient.
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treatment effect was significant (P = 
.005). This effect remained after adjust-
ment for the predefined baseline var-
iables (P = .045). Model performance 
was similar for a grade of 0 versus a 
grade greater than 0 and the full lin-
ear scale (Table E2 [online]). Because 
of greater clinical applicability of a two-
level score than a seven-level score, we 
chose to use the cutoff value 0 versus 
greater than 0. For this threshold, addi-
tional data analysis was performed.
Baseline Characteristics
At baseline, significant differences be-
tween patients with a COVES of 0 
and those with a COVES higher than 
0 included NIHSS (P , .001), Alberta 
Stroke Program Early CT Score (P = 
.039), and history of atrial fibrillation 
(P = .048) (Table 2). Especially nota-
ble is the difference in collateral vessel 
status between both groups (P , .001). 
As can be appreciated in Table 2, 60 
patients (48.8%) with COVES of 0 
had moderate or good collateral vessel 
status (grade 2 or 3) at baseline. The 
level of occlusion was also significantly 
different, with more patients with a 
COVES of 0 having a proximal occlu-
sion (P = .001). None of the other base-
line characteristics showed a significant 
difference.
Primary Outcome
No patients were lost to clinical fol-
low-up. In patients without venous 
opacification in the affected hemisphere 
(COVES 0), there was no shift on the 
mRS (adjusted common OR, 1.0; 95% 
CI: 0.5, 2.0). However, a large shift on 
the mRS was seen in favor of the in-
tervention group for patients with any 
degree of opacification on the affected 
side (COVES .0) (adjusted common 
OR, 2.2; 95% CI: 1.6, 4.1) (Table 3).
Secondary Outcomes
Patients in the intervention group with 
a COVES greater than 0 had a signifi-
cantly higher chance (27%) of becom-
ing functionally independent at 90 days 
(mRS, 0–2) (adjusted common OR, 
3.0; 95% CI: 1.7, 5.4), compared with 
1% of patients with a COVES of 0 (ad-
justed common OR, 1.4; 95% CI: 0.5, 
Table 2
Patient Characteristics at Baseline for the Optimal Cutoff Value of COVES 0 versus 
COVES Greater Than 0
Characteristic COVES 0* COVES .0* P Value
No. of patients 123 274
No. of men 74 (60.2) 155 (56.2) .456
Median age (y)†
 All patients 66 (54, 74) 65 (54, 76) .955
 Men 65 (53, 73) 63 (54, 74) .594
 Women 69 (56, 77) 66 (53, 77) .633
Median NIHSS† 20 (17, 23) 16 (13, 20) ,.001
Left hemisphere 61 (49.6) 155 (56.2) .224
Level of occlusion .001
 ICA 0 (0.0) 3 (1.1)
 ICA-T 47 (38.2) 64 (23.4)
 Segment M1 73 (59.4) 177 (64.6)
 Segment M2 3 (2.4) 30 (10.9)
Treatment with intravenous alteplase 112 (91.1) 245 (88.8) .493
Median onset to intravenous alteplase  
administration (min)†
90 (66, 122) 83(65, 110) .055
Median onset to randomization (min)†‡ 199 (148, 256) 205 (151, 266) .818
Collateral vessel score ,.001
 Grade 0 8 (6.5) 5 (1.8)
 Grade 1 55 (44.7) 46 (16.7)
 Grade 2 53 (43.1) 112 (40.7)
 Grade 3 7 (5.7) 111 (40.5)
ASPECTS subgroups§ .039
 0–4 8 (6.6) 14 (5.1)
 5–7 32 (26.2) 44 (16.1)
 8–10 82 (67.2) 216 (78.8)
Prestroke mRS score .410
 0 100 (81.3) 225 (81.5)
 1 8 (6.5) 27 (9.8)
 2 15 (12.2) 24 (8.7)
Mean systolic blood pressure (mm Hg)|| 145 (26) 145 (25) .874
Atrial fibrillation 40 (32.5) 63 (22.8) .048
History of diabetes mellitus 18 (14.6) 32 (11.6) .398
History of hypertension 52 (42.3) 127 (46.0) .489
History of ischemic stroke 15 (12.2) 27 (9.8) .470
History of myocardial infarction 17 (13.8) 35 (12.7) .755
History of peripheral artery disease 8 (6.5) 12 (4.3) .363
History of hyperlipidemia 28 (22.8) 67 (24.3) .744
History of smoking# 40 (32.5) 80 (29.0) .478
Current statin use 29 (23.6) 78 (28.3) .331
Current anticoagulant use 8 (6.5) 20 (7.2) .789
Current antiplatelet use 33 (26.8) 76 (27.5) .884
Note.—ASPECTS = Alberta Stroke Program Early CT Score (range, 0–10, with higher scores indicating less early ischemic 
changes), ICA-T = ICA terminus.
* Except where indicated, data are numbers of patients, with percentages in parentheses.
† Numbers in parentheses are interquartile ranges.
‡ Randomization time was missing in two patients.
§ ASPECTS was not available in one patient.
|| Systolic blood pressure at baseline was missing in one patient. Numbers in parentheses are standard deviations.
# Current smoking status was missing in 23 patients.
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cutoff values, could be considered asso-
ciated with treatment effect. Because a 
COVES of 0 versus greater than 0 was 
the optimal cutoff value in this study, this 
was the focus of our further analyses.
Of the comparable studies per-
formed until now, three used a multivein 
scoring method at baseline or dynamic 
CT angiography, one was focused on 
the internal cerebral vein asymmetry at 
baseline CT angiography, and one was 
focused on deep medullary vein asym-
metry at susceptibility-weighted MR 
imaging (14–16,21,22). One of these 
studies included a small proportion of 
our current study population (16). Al-
though a cortical vein score was also 
proposed in that study, it included only 
46 patients from two centers (out of 
the 500 patients in the 17 MR CLEAN 
centers). Furthermore, the association 
of the proposed scoring method with 
IAT benefit, which we believe to be es-
sential, was not analyzed in that study. 
Finally, as with previous studies, there 
is at least in part a focus on analysis 
of veins draining the deep cerebral 
systems (14–16,21,22). We believe the 
superficial venous system to be more 
relevant as it more accurately reflects 
the status of the microcirculation in the 
the number of symptomatic intracra-
nial hemorrhages between both groups 
(Table 4, Table E3 [online]).
Interobserver Analysis
Interobserver agreement for the full 
COVES was substantial, with a qua-
dratic weighted multirater k value 
of 0.73 (95% CI: 0.68, 0.79) (20). 
Agreement for the COVES cutoff value 
of 0 versus greater than 0 was moder-
ate, with an unweighted k value of 0.62 
(95% CI: 0.45, 0.80). The observers 
agreed in 83 of 100 cases.
Discussion
In this post hoc analysis of MR CLEAN, 
the degree of venous opacification in 
the affected hemisphere, as evaluated 
with baseline CT angiography, was as-
sociated with the effect of IAT in pa-
tients with MCA stroke. The presence 
of cortical vein opacification was re-
lated to a treatment benefit of IAT. Pa-
tients without venous opacification had 
no benefit from treatment.
Our study identifies an association 
between cortical vein asymmetry and 
IAT benefit. We were able to determine 
if the COVES, or one of its proposed 
3.6). However, interaction with treat-
ment effect did not reach statistical 
significance (adjusted P = .13) (Table 
3). For patients with a COVES greater 
than 0, NIHSS after 24 hours was lower 
in patients treated with IAT (b coeffi-
cient, 22.6; 95% CI: 24.2, 21.0), and 
the difference was statistically signifi-
cant. This was not the case in the pa-
tients with a COVES of 0 (b coefficient, 
0.024; 95% CI: 22.8, 2.8). Here too, 
no significant interaction was found 
(adjusted P = .069). The effect of IAT 
on recanalization or final infarct volume 
was comparable in the different groups.
Serious Adverse Events and Death
We found a significant difference in 
both 7- and 30-day mortality between 
the two groups (P  .001) (Table 4). 
The mortality rates in patients with a 
COVES of 0 at 7 days and 30 days after 
IAT (18.7% and 26.0%, respectively) 
were higher than those in patients 
with a COVES greater than 0 (5.8% 
and 13.4%, respectively) (P  .001 at 
7 days and P = .004 at 30 days). For 
grade greater than 0, a smaller propor-
tion of patients experienced a serious 
adverse event or stroke progression. 
There was no significant difference in 
Table 3
Primary and Secondary Effect Parameters according to COVES 
Outcome COVES 0 (n = 123) COVES .0 (n = 274) P Value*
Unadjusted Effect Adjusted Effect Unadjusted Effect Adjusted Effect Unadjusted Adjusted
Primary outcome: mRS score at  
90 days†
0.9 (0.5, 1.6) 1.0 (0.5, 2.0) 2.8 (1.8, 4.3) 2.2 (1.4, 3.5) .005 .044
Secondary outcome: clinical
 mRS 0–2† 1.1 (0.5, 2.6) 1.4 (0.5, 3.6) 3.6 (2.1, 6.1) 3.0 (1.7, 5.4) .024 .13
 NIHSS after 24 hours‡§ 0.5 (22.5, 3.5) 0.024 (22.8, 2.8) 24.1 (26.0, 22.2) 22.6 (24.2, 21.0) .010 .069
Secondary outcome: radiologic
 Recanalization on follow-up  
 vessel images at 24 hours†
6.1 (2.5, 15.5) 9.4 (3.1, 28.8) 6.3 (3.5, 11.3) 6.0 (3.3, 11.1) .62 .97
 Final infarct volume in  
 milliliters‡||
20.1 (20.5, 0.4) 20.1 (20.5, 0.3) 20.4 (26.7, 20.1) 20.4 (26.7, 20.1) .25 .49
Note.—This table lists the type of effect parameter (OR or linear regression coefficient), unadjusted and adjusted for age, NIHSS at baseline, time to randomization, previous stroke, atrial fibrillation, 
diabetes mellitus, and presence of ICA terminus occlusion. Numbers in parentheses are 95% CIs.
* P value of interaction term.
† Data are ORs.
‡ Data are b coefficients.
§ NIHSS was measured in survivors only.
|| Final infarct volume (log transformed) at unenhanced CT after 5 days (range, 3–9 days).
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threshold score of greater than 0 after 
data were analyzed. Thus, this thresh-
old might not perform optimally in 
other populations. Additional prospec-
tive investigations are needed to assess 
the reproducibility and clinical utility 
of the COVES. Third, a large variation 
in venous anatomy is commonly seen 
among patients. This could have influ-
enced our results, as some patients 
could have missing veins that would 
normally have been scored, and there-
fore did not add up to a COVES of 6. 
However, in the dichotomous analysis 
this issue does not play a role. More 
important, for assessment of cortical 
vein opacification, timing of CT angiog-
raphy through the entire venous phase 
is crucial. In MR CLEAN, most patients 
underwent single-phase CT angiogra-
phy. Single-phase CT angiography is 
widely available and routinely used in 
clinical stroke work-up. This leads to 
clinical applicability of the COVES. 
However, because patients with inad-
equate imaging timing were excluded, 
this could have created a selection bias 
in this post hoc analysis, owing to, for 
instance, exclusion of patients with a 
poor cardiac status. The use of time-re-
solved CT angiography techniques like 
multiphase or dynamic CT angiography 
could help minimize these limitations in 
future research (16).
The results of our analysis show a 
strong association between the opaci-
fication of cortical veins from an oc-
cluded territory and benefit from IAT. 
Table 4
Serious Adverse Events and Deaths
Event
COVES 0  
(n = 123)*
COVES .0  
(n = 274)* P Value
COVES 0  
Intervention Group  
(n = 62)*
COVES 0  
Control Group  
(n = 61)* P Value
COVES .0  
Intervention Group  
(n = 99)*
COVES .0  
Control Group  
(n = 156)* P Value
Death within 7 days 23 (18.7) 16 (5.8) ,.001 13 (21.0) 10 (16.4) .65 8 (6.7) 8 (5.1) .61
Death within 30 days 32 (26.0) 37 (13.4) .004 18 (29.0) 14 (23.0) .54 14 (11.7) 23 (14.7) .48
Hemicraniectomy 11 (8.9) 9 (3.3) .024 5 (8.1) 6 (9.8) .76 3 (2.5) 6 (3.8) .74
Patients with at least one SAE† 69 (56.1) 104 (37.7) .001 37 (59.7) 32 (52.5) .47 44 (36.7) 60 (38.5) .80
Symptomatic ICH 9 (7.3) 15 (5.4) .50 7 (11.3) 2 (3.3) .16 4 (3.3) 11 (7.1) .28
Progression of ischemic stroke 42 (25.9) 30 (12.7) .001 17 (27.4) 19 (31.1) .70 17 (14.2) 19 (12.2) .72
Note.—ICH = intracerebral hemorrhage, SAE = serious adverse event.
* Data are numbers of patients, with percentages in parentheses.
† Only first events of one type are listed. Patients experiencing multiple events of one type have been counted once.
MCA territory. We therefore omitted 
the deep cerebral venous system from 
the cortical vein score. Despite this 
fundamental difference and relatively 
small number of patients included in 
the other studies, an association be-
tween venous opacification and clinical 
outcome after IAT was reported. Our 
results confirm this association.
Our data support the expected 
worse outcome in patients with a prox-
imal or distal ICA occlusion. These pa-
tients are less likely to sustain venous 
drainage due to the decreased chance 
of having leptomeningeal collateral ves-
sels from the anterior cerebral artery 
territory backward to the MCA ter-
ritory. The only chance of filling the 
anterior circulation in ICA terminus 
occlusions is through an adequate an-
terior communicating artery from the 
contralateral side. Conversely, patients 
with segment M2 occlusion are more 
likely to exhibit venous drainage, as the 
still-patent MCA territory will continue 
to provide parenchymal blood flow with 
subsequent filling of the cortical venous 
territories.
Also of interest is the fact that a 
substantial proportion of patients with 
a COVES of 0 exhibited good collateral 
flow. We can speculate that microcir-
culation function, as well as possibly 
altered autoregulatory processes, ham-
pers local tissue perfusion, resulting in 
absent venous flow despite a good arte-
rial collateral status. In a study in the 
same population, a strong association 
between arterial collateral flow and IAT 
benefit was found (7). However, the 
group that did not benefit at all from 
IAT could not be conclusively identified. 
By applying the cortical vein score, it 
was possible to identify a group of pa-
tients who did not benefit from IAT. 
Additional analysis is required to com-
bine patient-specific data on arterial 
collateral vessel score and cortical vein 
score, allowing a better determination 
of the combined effect of use of both 
scoring systems.
The association between cortical 
vein opacification and IAT benefit in our 
study is not surprising if we take into 
account the already acknowledged value 
of venous asymmetry as seen during bal-
loon test occlusion of the ICA. A study 
in patients undergoing balloon occlusion 
for ICA aneurysms already showed a 
strong association between symmetrical 
venous opacification and neurologic tol-
erance of permanent occlusion (18). In 
that study, it was frequently seen that 
the delay from the arterial phase to the 
venous phase increases over time, which 
emphasizes the potential of venous as-
sessment as a surrogate marker for local 
microcirculation function.
Our study has limitations. The 
main analysis was performed by one 
observer, and the analysis of interob-
server agreement was performed only 
on a random subset of 100 patients, 
showing agreement in our final dichot-
omous outcome in only 83 of the 100 
patients. Second, we chose to use a 
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Our cortical vein scoring method is 
simple and has substantial interob-
server agreement. Moreover, it could 
potentially be a stronger predictor of 
IAT benefit than arterial collateral ves-
sel status because it better reflects mi-
crocirculation function. In the future, 
the COVES may play a role in the fur-
ther refinement of patient selection for 
IAT. In conclusion, patients with acute 
MCA stroke with absence of cortical 
vein opacification in the affected hemi-
sphere appeared to have no benefit 
from IAT, whereas patients with venous 
opacification were shown to benefit 
from IAT.
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Immediate Allergic Reactions to 
Gadolinium-based Contrast Agents: 
A Systematic Review and Meta-
Analysis
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Abstract, second sentence of Results 
should read as follows: The overall 
and severe rates of GBCA allergic-like 
adverse events were 9.2 and 0.52 per 
10 000 administrations, respectively: 
81% (539 of 662) were mild, 13% (86 
of 662) were moderate, and 6% (37 of 
662) were severe reactions.
Second paragraph of Results, first sen-
tence should read as follows: The over-
all rate of patients who had immedi-
ate allergic-like reactions was 9.2 per 
10 000 administrations and the overall 
rate of severe immediate allergic-like 
reactions was 0.52 per 10 000 admin-
istrations.
Third paragraph of Discussion, first 
sentence should read as follows: The 
favorable low reaction rate for nonionic 
linear GBCAs stands in contrast to their 
worrisome lower kinetic stability, which 
is thought to increase the risk of neph-
rogenic systemic fibrosis and gadolini-
um retention in the brain (22,43–45).
Fifth paragraph of Discussion, second 
sentence should read as follows: This 
greater rate of allergic-like reactions 
must be considered with other aspects 
of safety including the favorable stabil-
ity of macrocyclic agents that reduces 
risk of nephrogenic systemic fibrosis 
and gadolinium retention in the brain 
(43,47,48).
Table 3, under the column Comparison, 
fourth row head should read as follows: 
Non–protein binding linear vs macro-
cyclic
Table 5, under column Jung et al (7), 
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The legend for Figure 1b–d should read 
as follows: Images in unaffected hemi-
sphere show full opacification (arrow) 
of sphenoparietal sinus (b), superficial 
middle cerebral vein (c), and vein of 
Labbé (d).
This copy is for personal use only. To order printed copies, contact reprints@rsna.org
